A prospective pharmacogenetic study of 5FU/LV in high-risk stage II and III colon cancer patients.

被引：0
|
作者：
Mulder, K [1 ]
Scarfe, AG [1 ]
Koski, S [1 ]
Au, HJ [1 ]
Butts, C [1 ]
Fields, A [1 ]
Razavy, H [1 ]
Graham, K [1 ]
Cass, CE [1 ]
Sawyer, MB [1 ]
机构：
[1] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2067
引用
收藏
页码：143S / 143S
页数：1
相关论文
共 50 条
  • [41] Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: Final report of Intergroup 0089
    Haller, DG
    Catalano, PJ
    Macdonald, JS
    O'Rourke, MA
    Frontiera, MS
    Jackson, DV
    Mayer, RJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) : 8671 - 8678
  • [42] Identification of Risk Factors for Recurrence in High-Risk Stage II Colon Cancer
    Hatano, Satoshi
    Ishida, Hideyuki
    Ishibashi, Keiichiro
    Kumamoto, Kensuke
    Haga, Norihiro
    Miura, Ichiro
    INTERNATIONAL SURGERY, 2013, 98 (02) : 114 - 121
  • [43] Validation of the 12-Gene Colon Cancer Recurrence Score in NSABP C-07 As a Predictor of Recurrence in Patients With Stage II and III Colon Cancer Treated With Fluorouracil and Leucovorin (FU/LV) and FU/LV Plus Oxaliplatin
    Yothers, Greg
    O'Connell, Michael J.
    Lee, Mark
    Lopatin, Margarita
    Clark-Langone, Kim M.
    Millward, Carl
    Paik, Soonmyung
    Sharif, Saima
    Shak, Steven
    Wolmark, Norman
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (36) : 4512 - +
  • [44] ADJUVANT CHEMOTHERAPY IN HIGH-RISK STAGE II COLON CANCER.
    Lightner, A.
    Glyn, T.
    Parker, M.
    Tse, C.
    Abdelsattar, Z.
    Larson, D.
    Mathis, K.
    DISEASES OF THE COLON & RECTUM, 2016, 59 (05) : E293 - E293
  • [45] High-Risk Stage II Colon Cancer After Curative Resection
    Sato, Harunobu
    Maeda, Koutarou
    Sugihara, Kenichi
    Mochizuki, Hidetaka
    Kotake, Kenjiro
    Teramoto, Tetsuo
    Kameoka, Shingo
    Saito, Yukio
    Takahashi, Keiichi
    Hirai, Takashi
    Ohue, Masayuki
    Shirouzu, Kazuo
    Sakai, Yoshiharu
    Watanabe, Toshiaki
    Hirata, Koichi
    Hatakeyama, Katsuyoshi
    JOURNAL OF SURGICAL ONCOLOGY, 2011, 104 (01) : 45 - 52
  • [46] Two Pan-European trials in adjuvant colon cancer (PETACC 1&2):: The efficacy of Tomudex® compared to bolus 5-Fluorouracil/leucovorin (5-FU/LV); and high dose infusional 5-FU compared to bolus 5-FU/LV, in patients with stage III colon cancer
    Wils, J
    ANNALS OF ONCOLOGY, 1998, 9 : 45 - 45
  • [47] A randomized phase II of folfox4 compared with LV5FU2 in patients with previously untreated, completely resected stage II-III colon cancer
    Bensalem, A.
    Bouzid, K.
    ANNALS OF ONCOLOGY, 2008, 19 : 102 - 102
  • [48] Risk factors for recurrence in patients with high-risk stage II colon cancer after curative resection
    Ohge, H.
    Sadahiro, S.
    Sakamoto, K.
    Tsuchiya, T.
    Takahashi, T.
    Sato, T.
    Kondo, K.
    Ogata, Y.
    Baba, H.
    Itabashi, M.
    Ikeda, M.
    Hamada, M.
    Kusano, M.
    Hyodo, I.
    Sakamoto, J.
    Taguri, M.
    Morita, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S417 - S417
  • [49] Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair
    Hu, Huabin
    Wu, Zehua
    Wang, Chao
    Huang, Yan
    Zhang, Jianwei
    Cai, Yue
    Xie, Xiaoyu
    Li, Jianxia
    Shen, Cailu
    Li, Weiwei
    Ling, Jiayu
    Xu, Xuehu
    Deng, Yanhong
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [50] Cost-effectiveness of adjuvant chemotherapy for high-risk stage II and stage III colon cancer in South Africa
    Tan, Sarah Xinhui
    Pumpalova, Yoanna
    Rogers, Alexandra M. M.
    Bhatt, Kishan
    Herbst, Candice-lee
    Ruff, Paul
    Neugut, Alfred I. I.
    Hur, Chin
    CANCER MEDICINE, 2023, 12 (14): : 15515 - 15529
12345